ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6000-Perth-Royal-Perth-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT06824168
Haem
Phase 2
Recruiting
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission (
AC220-167
)
FLT3 inhibitor
KIT inhibitor
Acute myeloid leukaemia
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT06717347
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) (
MK-2140-010--2140-010
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06508658
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
EPCORE-DLBCL-4
)
anti-CD20 monoclonal antibody
antimetabolite
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06456463
Haem
Phase 2
Recruiting
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (
TRILLIUM
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
IL-3 diphtheria toxin fusion protein
antimetabolite
Acute myeloid leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
2024-512147-23-00--M24-287
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and/or in Combination With Azacitidine in Adults With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06163430
Haem
Phase 1
Recruiting
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (
TERN701-1012
)
BCR-ABL1 inhibitor,allosteric
Chronic myelogenous leukaemia
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06128629
Haem
Phase 3
Recruiting
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (
ITL-2001-CL-301
)
CRISPR-Cas9 gene-editing therapy,TTR-targeting
placebo
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05952037
Haem
Phase 2
Recruiting
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia (
U1111-1291-4524--BGB-11417-203
)
BTK inhibitor
Bcl2 inhibitor
Waldenström Macroglobulinaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05951049
Haem
Phase 2
Recruiting
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (
AT02-003
)
pan-amyloid-binding peptide fusion immunoglobulin
AL amyloidosis
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT05365659
Haem
Phase 1
Recruiting
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas (NHL) (
IKS03-01
)
anti-CD19 antibody-drug conjugate
B-cell lymphoma
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT05139017
Haem
Phase 2
Recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (
VLS-101--2140-003
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04973605
Haem
Phase 1
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
2023-507751-30-00--BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04964518
Haem
Phase 1
Recruiting
A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (
APG2575AU101
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Solid tumour
VIC
3066 - Epping - Northern Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04655118
Haem
Phase 2
Recruiting
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis (
TL-895-201
)
BTK inhibitor
Myelofibrosis
Systemic mastocytosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04637763
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (
CB10A
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04581512
Haem
Phase 1
Recruiting
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies (
EP0042-101
)
FLT3/Aurora inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
WA
6000 - Perth - Royal Perth Hospital
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, =80 Years, or Frail =75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04170283
Haem
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
4120 - Greenslopes - Greenslopes Private Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03888105
Haem
Phase 2
Recruiting
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (
ELM-2
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
NCT03165734
Haem
Phase 3
Recruiting
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/µL)(
PACIFICA
)
JAK2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT02386800
Haem
Phase 4
Recruiting
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies (
2014-003527-22--CINC424A2X01B
)
JAK1/JAK2 inhibitor
pan-HDAC inhibitor
Acute myeloid leukaemia
Myelofibrosis
Polycythemia vera
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12625001031459
Haem
Phase 2
Not yet recruiting
Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.
Cyclophosphamide
Fludarabine
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Multiple myeloma
WA
6000 - Perth - Royal Perth Hospital
ACTRN12621001419853
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (
OP-1250-002
)
CDK4/6 inhibitor
complete estrogen receptor antagonist
Breast cancer
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 42 in
/home/topowadl/articanz.org/table.php
on line
430
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M-(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
Cyclophosphamide
Fludarabine
Radiotherapy
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
Not yet recruiting (2)
Enrolling by invitation (1)
Recruitment Country and State
WA (27)
VIC (22)
QLD (17)
NSW (16)
SA (10)
NZ (6)
ACT (5)
TAS (2)
Phase
Phase 1 (10)
Phase 1 / Phase 2 (1)
Phase 2 (9)
Phase 3 (7)
Phase 4 (1)
Trial Type
Haem (25)
Paed (2)
Advanced (1)
Cancer Therapy Class
CD20
25%
Bcl2
18%
DNA methyltransferase
14%
BTK
14%
cereblon
11%
FLT3
7%
ROR1
7%
CD19
7%
CD79b
7%
JAK1
7%
JAK2
7%
KIT
4%
ISR
4%
multikinase
4%
BCR-ABL1
4%
TTR
4%
amyloid
4%
CD38
4%
proteasome
4%
KMT2A
4%
AURKA
4%
AURKB
4%
Aurora
4%
PD-1
4%
PD-1/PD-L1
4%
HDAC
4%
pan-HDAC
4%
CDK4
4%
CDK6
4%
ER
4%
oestrogen axis
4%
GM-CSF
4%
Facility
6000 - Perth - Royal Perth Hospital (28)
3168 - Clayton - Monash Medical Centre (9)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
3066 - Epping - Northern Hospital (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (4)
2605 - Garran - The Canberra Hospital (4)
2139 - Concord - Concord Repatriation General Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2640 - Albury - Albury Wodonga Regional Cancer Centre (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
4215 - Southport - Gold Coast University Hospital (2)
NA
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2217 - Kogarah - St George Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
2500 - Wollongong - Wollongong Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4217 - Benowa - Pindara Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Lymphoma
B-cell malignancy
Non-Hodgkin's lymphoma
Mature B-cell malignancy
Myeloid leukaemia
B-cell lymphoma
Acute myeloid leukaemia
Myeloproliferative neoplasm
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoid leukaemia
Solid tumour
Plasma cell disorder
Myelofibrosis
Chronic lymphocytic leukaemia
Myelodysplastic syndrome
Multiple myeloma
Acute lymphoblastic leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic/Myeloproliferative disease
Polycythemia vera
Small lymphocytic lymphoma
Chronic leukaemia
Chronic myelogenous leukaemia
Waldenström Macroglobulinaemia
AL amyloidosis
Amyloidosis
Follicular lymphoma
Mantle cell lymphoma
Mast cell disorder
Systemic mastocytosis
Breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy